孙伟娜;王镁;

• 1:辽宁中医药大学
• 2:辽宁中医药大学附属医院

摘要(Abstract)：

目的探讨中药复方糖肾安对实验性2型糖尿病大鼠肾脏ROS水平、Nrf2、HO-1表达的影响。方法70只健康SD大鼠随机分为正常组(n=10)和造模组(n=60)。造模组大鼠高糖高脂饮食4周后一次性腹腔注射STZ(35 mg/kg)建立2型糖尿病大鼠模型,将成模的大鼠随机分为模型组、糖肾安低、中、高剂量组、西药组。药物治疗8周后,用流式细胞仪检测ROS水平,用定量RT-PCR、Western blot检测Nrf2、HO-1表达情况。结果各治疗组ROS水平均高于正常组(P<0.01),糖肾安组ROS水平均明显低于模型组(P<0.01)。各治疗组Nrf2、HO-1表达均低于正常组(P<0.01),糖肾安中、高剂量组的表达较高,高于模型组(P<0.01)。结论中药复方糖肾安可能通过激活抗氧化应激Nrf2/ARE通路,诱导糖尿病大鼠肾脏Nrf2、HO-1的表达,降低ROS水平,改善肾脏炎症反应,从而起到肾脏保护作用。

关键词(KeyWords)： 糖肾安煎剂;厄贝沙坦;氧化应激;糖尿病大鼠

Abstract:

Keywords:

基金项目(Foundation): 沈阳市科技局项目(F14-231-1-11)

作者(Author): 孙伟娜;王镁;

Email:

DOI: 10.13463/j.cnki.jlzyy.2016.12.019

参考文献(References)：

• [1]REUTENS A T,ATKINSTKINS R C.Epidemiology of diabetic nephropathy[J].Contrib Nephrol,2011,170(1):1-7.
• [2]NGUYEN T,NIOI P,PICKETT CB.The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress[J].J Biol Chem,2009,284(20):13291-13295.
• [3]MATTEUCCI E,GIAMPIETRO O.Proposal open for discussion:defining agreed diagnostic procedures in experimental diabetes reasearch[J].J Ethnopharmacol,2008,115(2):163-172.
• [4]SHIOSE A,KURODA J,TSURUYA K,et al.A Novel Superoxide-producing NAD(P)H Oxidase in Kidney[J].JBC,2001,276(2):1417-1423.
• [5]BANDAY AA,MARWAHA A,TALLAM LS,et al.Tempol Reduces Oxidative Stress,Improves Insulin Sensitivity,Decreases Renal Dopamine D1 Receptor Hyperphosphorylation and Restores D1 Receptor-G-protein Coupling and Function in Obese Zucker Rats[J].Diabetes,2005,(54):2219-2226.
• [6]FORBES JM,COUGHLAN MT,COOPER ME.Oxidative stress as a major culprit in kidney disease in diabetes[J].Diabetes,2008,57(6):1446-1454.
• [7]SINGH DK,WINOCOUR P,FARRINGTON K.Oxidative stress in early diabetic nephropathy:fueling the fire[J].Nat Rev Endocrinol,2011,7(3):176-84.
• [8]NGUYEN T,NION P,PICKETT CB.The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress[J].J Biol Chem,2009,284(20):13291-13295.
• [9]KASPAR JW,NITURE SK,JAISWAL AK.Nrf2:l Nrf2(Keapl)signaling in oxidative stress[J].Free Radical Biology and Medicine,2009,47(9):1304-1309.
• [10]DE HAAN JB.Nrf2 activators as attractive therapeutics for diabetic nephropathy[J].Diabetes,2011,60(11):2683-2684.
• [11]ZHANG Q,PI J,WOODS CG,et al.A systems biology perspective on Nrf2-mediated antioxidant response[J].Toxicol Appl Pharmacol,2010,244(1):84-97.
• [12]曹光,王镁.糖肾安煎剂对糖尿病大鼠氧化应激影响的研究[J].中华中医药学刊,2009,27(4):761-762.
• [13]刘仪红,田浩明.黄芪治疗糖尿病肾病的系统评价[J].中国循证医学杂志,2007,7(10):715-727.
• [14]杨瑞峰.黄芪注射液治疗糖尿病肾病56例[J].医药论坛杂志,2006,27(16):84.
• [15]徐刚,鄢巨振,王当金,等.肾脏病患者血与尿硒含量变化及其临床意义[J].中华肾脏病杂志,1998,14(6):387-388.
• [16]宋春晖,陈大舜.以“血瘀”立论辨证论治糖尿病肾病的研究进展[J].辽宁中医药大学学报,2010,12(3):43-45.
• [17]胡波,范红伟,鲍军强,等.丹参对糖尿病肾损害大鼠水液代谢异常与水通道蛋白调节机制探讨[J].时珍国医国药,2011,22(2):356-358.
• [18]李观林.山茱萸中环烯醚萜苷类的研究进展[J].亚太传统医药,2014,10(18):48-49.
• [19]CERIELLO A,ASSALONI R,DA ROS R,et al.Effect of atorvastatin and irbesartan,alone and in combination,on postprandial endothelial dysfunction,oxidative stress,and inflammation in type 2 diabetic patients[J].Circulation,2005,111(19):2518-2524.
• [20]况瑜天,何海生.小剂量厄贝沙坦治疗2型糖尿病早期肾病的临床研究[J].中国药业,2010,19(9):62-63.